SecBot SecBot
SECBOTREPLAY Home › Report › ERAS

ERAS · Erasca reported fourth quarter and full year 2025 financial results,…

Erasca, Inc. · PRESS-RELEASE filed Mar 12, 2026 at 16:01 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 12, 2026 at 16:01 ET

Erasca reported fourth quarter and full year 2025 financial results, highlighted by reduced net losses and a strong cash position bolstered by a $259 million financing in January 2026. The company emphasized early clinical progress in its RAS-targeting pipeline, including partial responses for ERAS-0015 across multiple tumor types, and expanded its licensing rights globally. Phase 1 data for ERAS-0015 and ERAS-4001 are expected in H1 and H2 2026, respectively.

  • Cash, cash equivalents, and marketable securities were $341.8 million as of December 31, 2025, down from $440.5 million a year prior.
  • Completed upsized public offering in January 2026, raising $258.8 million in gross proceeds, bringing pro forma cash to $434 million.
  • Cash expected to fund operations into H2 2028.
  • Net loss decreased to $29.1 million in Q4 2025 from $32.2 million in Q4 2024; full-year net loss improved to $124.5 million from $161.7 million in 2024.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access